MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
6.58
-0.15
-2.23%
After Hours: 6.60 +0.02 +0.30% 19:26 12/31 EST
OPEN
6.66
PREV CLOSE
6.73
HIGH
6.72
LOW
6.48
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
1.100
MARKET CAP
424.87M
P/E (TTM)
-3.6904
1D
5D
1M
3M
1Y
5Y
1D
Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3
Seeking Alpha · 12/30/2025 20:42
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
NASDAQ · 12/29/2025 17:00
Weekly Report: what happened at IMRX last week (1222-1226)?
Weekly Report · 12/29/2025 09:24
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Benzinga · 12/24/2025 16:06
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial
NASDAQ · 12/24/2025 08:41
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP
TipRanks · 12/23/2025 13:11
Immuneering To Provide 12-Month Overall Survival From Its Current Phase 2a Clinical Study Of Atebimetinib + Modified Gemcitabine In Pancreatic Participants
Benzinga · 12/23/2025 13:03
Immuneering to Announce 12-Month Survival Data from Phase 2a Pancreatic Cancer Trial
Reuters · 12/23/2025 13:00
More
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.